233 related articles for article (PubMed ID: 38153100)
1. Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?
Visentin A; Puthenparampil M; Briani C
Expert Opin Investig Drugs; 2023; 32(12):1105-1111. PubMed ID: 38153100
[TBL] [Abstract][Full Text] [Related]
2. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Hatashima A; Karami M; Shadman M
Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
[TBL] [Abstract][Full Text] [Related]
3. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
[TBL] [Abstract][Full Text] [Related]
4. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Easaw S; Ezzati S; Coombs CC
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):697-704. PubMed ID: 37544810
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
Stephens DM; Byrd JC
Blood; 2021 Sep; 138(13):1099-1109. PubMed ID: 34320163
[TBL] [Abstract][Full Text] [Related]
7. Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.
Mouhssine S; Maher N; Matti BF; Alwan AF; Gaidano G
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542207
[TBL] [Abstract][Full Text] [Related]
8. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Feng Y; Duan W; Cu X; Liang C; Xin M
Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
[TBL] [Abstract][Full Text] [Related]
9. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
10. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Palma M; Mulder TA; Ă–sterborg A
Front Immunol; 2021; 12():686768. PubMed ID: 34276674
[TBL] [Abstract][Full Text] [Related]
11. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
12. BTK Inhibitors in Haematology: Beyond B Cell Malignancies.
Leitinger DE; Kaplan DZ
Transfus Med Rev; 2022 Oct; 36(4):239-245. PubMed ID: 36376164
[TBL] [Abstract][Full Text] [Related]
13. Practical management of chronic lymphocytic leukemia with acalabrutinib.
Kuss B; Nagarajan C; Hsieh WS; Cheah CY
Leuk Lymphoma; 2022 Dec; 63(12):2785-2794. PubMed ID: 35852229
[TBL] [Abstract][Full Text] [Related]
14. Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.
Shirley M
Target Oncol; 2022 Jan; 17(1):69-84. PubMed ID: 34905129
[TBL] [Abstract][Full Text] [Related]
15. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
16. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
17. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Tang CPS; McMullen J; Tam C
Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
20. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]